Complete therapeutic response to anti-PD1 therapy in patient with advanced melanoma and resistance to targeted therapy of BRAF inhibitors

Abstract

This clinical case describes patient with metastatic melanoma, who progressed after the first month of targeted therapy withBRAF and MEK inhibitors. The therapeutic effect came shortly after initiation of treatment with anti-PD1 therapy pembrolizumabwith a complete response after 4 months.

The complete response now takes over 30 months. Possible mechanisms of so-calledprimary resistance of targeted BRAF inhibitors are described is discussion.

Keywords

• metastatic melanoma
• targeted therapy
• primary resistance
• anti-PD1 therapy